<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Linezolid</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00601</strong>&#160; (APRD01073, DB08769)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Linezolid is a synthetic antibiotic, the first of the oxazolidinone class, used for the treatment of infections caused by multi-resistant bacteria including streptococcus and methicillin-resistant Staphylococcus aureus (<span class="caps">MRSA</span>). The drug works by inhibiting the initiation of bacterial protein synthesis.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00601/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00601/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00601.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00601.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00601.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00601.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00601.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00601">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Linezolid</td><td>German</td><td>INN</td></tr><tr><td>Linezolid</td><td>Spanish</td><td>INN</td></tr><tr><td>Linezolide</td><td>French</td><td>INN</td></tr><tr><td>Linezolidum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Antizolid</td><td>Verisfield</td></tr><tr><td>Linosept</td><td>Orion</td></tr><tr><td>Linozid</td><td>Orion</td></tr><tr><td>Lizbid</td><td>Abbott</td></tr><tr><td>Lizemox</td><td>Molekule</td></tr><tr><td>Lizolid</td><td>Glenmark</td></tr><tr><td>Xolid</td><td>Corona</td></tr><tr><td>Zenix</td><td>Hemofarm</td></tr><tr><td>Zizolid</td><td>Biofarma</td></tr><tr><td>Zodlin</td><td>FDC</td></tr><tr><td>Zolinid</td><td>Teva</td></tr><tr><td>Zyvox</td><td>Pfizer</td></tr><tr><td>Zyvoxam</td><td>Pfizer</td></tr><tr><td>Zyvoxid</td><td>Pfizer</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anti-bacterial-agents">Anti-Bacterial Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>165800-03-3</td></tr><tr><th>Weight</th><td>Average: 337.3461<br>Monoisotopic: 337.143784348</td></tr><tr><th>Chemical Formula</th><td>C<sub>16</sub>H<sub>20</sub>FN<sub>3</sub>O<sub>4</sub></td></tr><tr><th>InChI Key</th><td>TYZROVQLWOKYKF-ZDUSSCGKSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C16H20FN3O4/c1-11(21)18-9-13-10-20(16(22)24-13)12-2-3-15(14(17)8-12)19-4-6-23-7-5-19/h2-3,8,13H,4-7,9-10H2,1H3,(H,18,21)/t13-/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">N-{[(5S)-3-[3-fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CC(=O)NC[C@H]1CN(C(=O)O1)C1=CC(F)=C(C=C1)N1CCOCC1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Oxazinanes</td></tr><tr><th>Subclass</th><td>Morpholines</td></tr><tr><th>Direct parent</th><td>Phenylmorpholines</td></tr><tr><th>Alternative parents</th><td>Fluorobenzenes; Oxazolidinediones; Aryl Fluorides; Secondary Carboxylic Acid Amides; Carbamic Acids and Derivatives; Tertiary Amines; Polyamines; Enolates; Ethers; Carboxylic Acids; Organofluorides</td></tr><tr><th>Substituents</th><td>oxazolidinedione; fluorobenzene; aryl fluoride; aryl halide; benzene; tertiary amine; secondary carboxylic acid amide; carboxamide group; carbamic acid derivative; polyamine; carboxylic acid derivative; enolate; ether; carboxylic acid; organohalogen; organofluoride; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the phenylmorpholines. These are aromatic compounds containing a morpholine ring and a benzene ring linked to each other through a CC or a CN bond.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of bacterial infections caused by susceptible strains of vancomycin resistant <i>Enterococcus faecium</i>, <i>Staphylococcal aureus</i> (methicillin resistant and susceptible strains), <i>Streptococcus pneumoniae</i>, <i>Streptococcus pyogenes</i>, <i>Streptococcus agalactiae</i>.</td></tr><tr><th>Pharmacodynamics</th><td>Linezolid is a synthetic antibacterial agent of a new class of antibiotics, the oxazolidinones, which has clinical utility in the treatment of infections caused by aerobic Gram-positive bacteria. The in vitro spectrum of activity of linezolid also includes certain Gram-negative bacteria and anaerobic bacteria. Susceptible organisms include methicillin- and vancomycin-resistant staphylococci, vancomycin-resistant enterococci, penicillin-resistant pneumococci and anaerobes. Oxazolidinones inhibit protein synthesis by binding at the P site at the ribosomal 50S subunit. Resistance to other protein synthesis inhibitors does not affect oxazolidinone activity, however rare development of oxazolidinone resistance cases, associated with 23S rRNA alterations during treatment have been reported. Linezolid inhibits bacterial protein synthesis through a mechanism of action different from that of other antibacterial agents; therefore, cross-resistance between linezolid and other classes of antibiotics is unlikely.</td></tr><tr><th>Mechanism of action</th><td>Linezolid is a synthetic antibacterial agent of the oxazolidinone class of antibiotics. It has in vitro activity against aerobic Gram positive bacteria, certain Gram negative bacteria and anaerobic microorganisms. It selectively inhibits bacterial protein synthesis through binding to sites on the bacterial ribosome and prevents the formation of a functional 70S-initiation complex. Specifically, linezolid binds to a site on the bacterial 23S ribosomal RNA of the 50S subunit and prevents the formation of a functional 70S initiation complex, which is an essential component of the bacterial translation process. The results of time-kill studies have shown linezolid to be bacteriostatic against enterococci and staphylococci. For streptococci, linezolid was found to be bactericidal for the majority of strains. Linezolid is also a reversible, nonselective inhibitor of monoamine oxidase. Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents.</td></tr><tr><th>Absorption</th><td>Linezolid is rapidly and extensively absorbed after oral dosing. Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%.</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>40 to 50 L [healthy adult volunteers]</li>
</ul></td></tr><tr><th>Protein binding</th><td>31%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Linezolid is primarily metabolized by oxidation of the morpholine ring, which results in two inactive ring-opened carboxylic acid metabolites: the aminoethoxyacetic acid metabolite (A), and the hydroxyethyl glycine metabolite</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Linezolid</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00797">aminoethoxyacetic acid</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/818">Details</a></td></tr><tr><td>Linezolid</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01017">Hydroxyethyl glycine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1040">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>4.5-5.5 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Clinical signs of acute toxicity lead to decreased activity, ataxia, vomiting and tremors.</td></tr><tr><th>Affected organisms</th><td><ul><li>Gram negative and gram positive bacteria</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>1.0</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9363</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.8866</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.5881</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.7599</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6478</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7469</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7898</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.5904</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7811</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8174</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8112</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5664</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7563</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.5544</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.6839
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8916
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9895
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.4938 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.7883
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.6297
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Pharmacia and upjohn co</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.fresenius-kabi.com">Fresenius Kabi AB</a></li>
<li>Lake Erie Medical and Surgical Supply</li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.pfizer.com">Pfizer Inc.</a></li>
<li><a href="http://www.pharmaciaupjohn.com">Pharmacia Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Solution</td><td>Intravenous</td><td></td></tr><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01393">Bezafibrate</a></td><td>MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate. Avoid concomitant use of bezafibrate with monoamine oxidase inhibitors (MAOIs) like linezolid. </td></tr><tr><td><a href="/drugs/DB00484">Brimonidine</a></td><td>MAO Inhibitors like linezolid may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic). The concomitant use of monoamine oxidase inhibitors and ophthalmic alpha2 agonists is contraindicated. </td></tr><tr><td><a href="/drugs/DB00921">Buprenorphine</a></td><td>Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like linezolid. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects. </td></tr><tr><td><a href="/drugs/DB00215">Citalopram</a></td><td>Combination associated with possible serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB06700">Desvenlafaxine</a></td><td>Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00841">Dobutamine</a></td><td>Possible increase of arterial pressure</td></tr><tr><td><a href="/drugs/DB00988">Dopamine</a></td><td>Possible increase of arterial pressure</td></tr><tr><td><a href="/drugs/DB01363">Ephedra</a></td><td>Possible increase of arterial pressure</td></tr><tr><td><a href="/drugs/DB01364">Ephedrine</a></td><td>Possible increase of arterial pressure</td></tr><tr><td><a href="/drugs/DB00668">Epinephrine</a></td><td>Possible increase of arterial pressure</td></tr><tr><td><a href="/drugs/DB01175">Escitalopram</a></td><td>Combination associated with possible serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB01288">Fenoterol</a></td><td>Possible increase of arterial pressure</td></tr><tr><td><a href="/drugs/DB00472">Fluoxetine</a></td><td>Linezolide, a MAO inhibitor, may increase the serotonergic effect of fluoxetine, a SSRI. Increased for of serotonin syndrome. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00176">Fluvoxamine</a></td><td>Combination associated with possible serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB01064">Isoprenaline</a></td><td>Possible increase of arterial pressure</td></tr><tr><td><a href="/drugs/DB01365">Mephentermine</a></td><td>Possible increase of arterial pressure</td></tr><tr><td><a href="/drugs/DB00610">Metaraminol</a></td><td>Possible increase of arterial pressure</td></tr><tr><td><a href="/drugs/DB00723">Methoxamine</a></td><td>Possible increase of arterial pressure</td></tr><tr><td><a href="/drugs/DB01149">Nefazodone</a></td><td>Combination associated with possible serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB00368">Norepinephrine</a></td><td>Possible increase of arterial pressure</td></tr><tr><td><a href="/drugs/DB00816">Orciprenaline</a></td><td>Possible increase of arterial pressure</td></tr><tr><td><a href="/drugs/DB00715">Paroxetine</a></td><td>Combination associated with possible serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB00388">Phenylephrine</a></td><td>Possible increase of arterial pressure</td></tr><tr><td><a href="/drugs/DB00397">Phenylpropanolamine</a></td><td>Possible increase of arterial pressure</td></tr><tr><td><a href="/drugs/DB01291">Pirbuterol</a></td><td>Possible increase of arterial pressure</td></tr><tr><td><a href="/drugs/DB01366">Procaterol</a></td><td>Possible increase of arterial pressure</td></tr><tr><td><a href="/drugs/DB00852">Pseudoephedrine</a></td><td>Possible increase of arterial pressure</td></tr><tr><td><a href="/drugs/DB01001">Salbutamol</a></td><td>Possible increase of arterial pressure</td></tr><tr><td><a href="/drugs/DB01104">Sertraline</a></td><td>Combination associated with possible serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB00871">Terbutaline</a></td><td>Possible increase of arterial pressure</td></tr><tr><td><a href="/drugs/DB04844">Tetrabenazine</a></td><td>Tetrabenazine may increase the adverse/toxic effects of Linezolid. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00323">Tolcapone</a></td><td>Tolcapone and Linezolid decrease the metabolism of endogenous catecholamines. Concomitant therapy may result in increased catecholamine effects. Consider alternate therapy or use cautiously and monitor for increased catecholamine effects. </td></tr><tr><td><a href="/drugs/DB00193">Tramadol</a></td><td>Tramadol increases the risk of serotonin syndrome and seizure induction by the MAO inhibitor, Linezolid. </td></tr><tr><td><a href="/drugs/DB00752">Tranylcypromine</a></td><td>The MAO inhibitor, Tranylcypromine, may increase the adverse effects of Linezolid. These agents should not be administered within 14 days of each other. </td></tr><tr><td><a href="/drugs/DB00656">Trazodone</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00726">Trimipramine</a></td><td>Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Avoid combination or monitor for symptoms of serotonin syndrome and/or hypertensive crisis. </td></tr><tr><td><a href="/drugs/DB00285">Venlafaxine</a></td><td>Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB06684">Vilazodone</a></td><td>MAO Inhibitors may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome. Avoid combination.</td></tr><tr><td><a href="/drugs/DB00315">Zolmitriptan</a></td><td>The MAO inhibitor, linezolid, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing linezolid are contraindicated. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Take without regard to meals.</li></ul></td></tr></tbody></table>